#USA #Barcelona #Gout Treatment #SAP-001 #Shanton Pharma

Shanton Pharma to Present Data from SAP-001 Study at EULAR 2025

Shanton Pharma, a clinical-stage biotechnology company specializing in innovative gout treatments, has announced its participation in the upcoming EULAR 2025 Congress. The event, scheduled to take place from June 11 to June 14, 2025, in Barcelona, will feature a presentation of topline data from the company's Phase 2b clinical trial involving SAP-001. This investigational compound is making waves in the medical community for its promising results in refractory gout patients, those who struggle with conventional treatments.

The European Alliance of Associations for Rheumatology (EULAR) is recognized for its rigorous standards, with the review committee approving Shanton’s late-breaking abstract for an oral presentation—a sign of high relevance and urgency in rheumatology. Dr. Wenfeng Miao, Chief Medical Officer of Shanton, expressed enthusiasm for sharing their research findings, emphasizing the need for new therapeutic options for patients who have not benefitted from traditional Gout management practices.

Gout, characterized by severe pain and inflammation due to the accumulation of uric acid crystals in the joints, has long been managed using Urate Lowering Therapies (ULT). However, many patients find these standard treatments ineffective or intolerable. SAP-001 aims to address this gap by targeting a unique renal transporter involved in urate excretion, offering a potentially new approach to lower uric acid levels in the body. According to preliminary results from earlier Phase 1 and 2a studies, SAP-001 has demonstrated significant urate-lowering effects with a favorable safety profile, positioning it as a potential leader in gout medication.

The focus of Shanton Pharma is to tackle the unmet medical needs associated with gout, specifically for patients who do not respond adequately to existing therapies. The company, established in 2016 and headquartered in Singapore, has been dedicated to developing effective treatments for hyperuricemia and gout. With research activities spanning across the US, China, and Singapore, Shanton aims to leverage its innovative drug development processes to improve patient outcomes in this challenging domain.

In the context of the EULAR Congress, Shanton Pharma is poised to share data that could alter the landscape of gout management. The company’s commitment to addressing refractory gout has implications not only for patients but also for healthcare providers seeking new options in an often frustrating treatment pathway for their patients.

As EULAR 2025 approaches, the anticipation surrounding SAP-001 continues to build, setting the stage for potentially groundbreaking developments in rheumatology. For more updates on Shanton Pharma and its innovative work, interested parties can visit their official website.

Conclusion

Shanton Pharma's upcoming presentation at EULAR 2025 represents a critical step forward in the pursuit of effective treatments for refractory gout. In an area where patient needs continue to outpace available solutions, SAP-001 could provide the breakthrough that many have been waiting for. As clinicians eagerly await the findings from Shanton’s Phase 2b study, the global rheumatology community remains hopeful for advancements that can significantly improve patient care and quality of life in dealing with gout.